Suzanne Schindler, MD, PhD, Washington University School of Medicine in St. Louis, St. Louis, MO, discusses a head-to-head evaluation of leading blood tests for amyloid pathology in Alzheimer’s disease (AD). The study compared six leading blood tests and found that ptau217 tests performed well in classifying amyloid status in cognitively impaired individuals. The addition of the Aβ42/40 ratio was particularly useful in cognitively unimpaired individuals, so it may have value in prevention clinical trials. The ptau217 biomarker was the best correlated with all outcome measures evaluated compared to other biomarkers, so Prof. Schindler recommends only using tests that include ptau217 in diagnosis. This interview took place at the Alzheimer’s Association International Conference® (AAIC) 2024 in Philadelphia, PA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
